Clinical Trial Update: An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload [Phase 3]

View source ↗

Summary

Extension study results for deferasirox (ICL670) used to treat transfusional iron overload in patients with β-thalassemia; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia
• Transfusional Iron Overload

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Transfusional Iron Overload in β-thalassemia | Phase 3 | Status: COMPLETED | Results posted: 2011-05-02